ORLANDO — In this video from the American Academy of Ophthalmology meeting, Kenneth C. Fan, MD, MBA, highlights outcomes of the STARLIGHT study in Stargardt disease.
The 48-week open-label phase 2 clinical trial looked at the use of MCO-010 (Nanoscope Therapeutics) in patients with severe stage Stargardt disease. It included six patients, three with a macular phenotype and three with a panretinal phenotype.
MCO-010 is a transgene that encodes for an opsin that has an affinity for bipolar cells and improves the sensitivity of bipolar cells to ambient light. The opsin is delivered